IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati

Ionis granted Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization rights. The deal provides Ionis with upfront and royalty payments, adding non-dilutive value to the program and validating the asset’s commercial potential outside the U.S. The announcement is positive for both companies but is likely to have only a modest near-term share-price impact.

Analysis

Ionis granted Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization rights. The deal provides Ionis with upfront and royalty payments, adding non-dilutive value to the program and validating the asset’s commercial potential outside the U.S. The announcement is positive for both companies but is likely to have only a modest near-term share-price impact.